Beyond Simple Inhibition: How Inavolisib Co-opts FGFR2 to Eradicate PIK3CA-Mutated Tumors
A Phase 1 study and preclinical analysis reveal that inavolisib, a PI3Kα inhibitor and degrader, leverages FGFR2 signaling to enhance the degradation of mutated p110α, yielding superior clinical benefits in PIK3CA-mutated solid tumors.
